ENTITY
I-Mab

I-Mab (IMAB US)

56
Analysis
Health CareChina
I-Mab operates as a clinical stage biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of novel biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab conducts business in China.
more
Refresh
09 Sep 2020 20:57

Remain Overweight EM Relative To EAFE

The MSCI EM index (local currency) remains in an uptrend and is testing all-time highs set in January 2018 near 65,800; as long as the index is...

Logo
355 Views
Share
bullishI-Mab
08 Jul 2020 15:10

I-Mab (天境生物) Lock-Up Expiry: A Differentiated Immunotherapy Player Worth Reverse Inquiry

I-Mab was listed in the US  on Jan 17th and returned 96% since listing. I-Mab has a highly differentiated two segments of products, including...

Logo
359 Views
Share
bullishDada Nexus
05 Jun 2020 13:09

Dada Nexus (达达集团) IPO Trading - Larger Deal Size with Decent Potential Upside

Dada Nexus (DADA US) raised US$336m at US$16 per share, the mid-point of its IPO price range. The number of ADS sold was upsized by about 27%, to...

Share
bullishI-Mab
17 Jan 2020 11:27

I-Mab (天境生物) IPO Trading: Tiny Float and Undemanding Valuation

I-Mab (IMAB US) raised USD 104 million at USD 14.0 per ADS, above the mid-point of the IPO price range. I-Mab will start trading today. We have...

Logo
433 Views
Share
bullishLuckin Coffee
12 Jan 2020 12:13

ECM Weekly (12 Jan 2020) - Jiumaojiu, I-Mab, Phoenix Tree, Burger King India

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. We are...

Share
x